In a phase 2 trial, 111 patients with IPF received either intravenous recombinant human Pentraxin 2 (at a dose of 10 mg/kg) or placebo every 4 weeks for 24 weeks. The gene discussed is APCS; the disease is idiopathic interstitial pneumonia.